L-Asparaginase treatment induces reversible immunoregulatory and immunosuppressive effects in non-malignant B cells in a model of T-cell dependent B cell activation
Amar Hadzic, Maria Alejandra Garcia-MarqueziD, Pol Bannasch, Nina Haindl, Katharina FreyiD, Martin Kirmaier, Maximilian A. FunkiD, Anneli Tischmacher, Jingke Tu, Adriano Carboniero, Ludovica Vona, Sabine Oganesian, Lena Muschik, Hans SchlößeriD, Martin VaethiD, Werner SchmitziD, Michael von Bergwelt‐BaildoniD, David M. Cordas dos SantosiD, Sebastian TheurichiD
Abstract
Metabolic reprogramming is critical for immune cell adaptation upon activation to exert full functionality with amino acids being a key metabolic factor. While L-asparagine is a non- essential amino acid it turns out to be conditionally essential in malignant B cells due to defective asparagine synthetase making L-asparaginase a commonly used chemotherapeutic agent. Off-target enzymatic activity including glutaminolysis impacting crucial immune function. However, its effects on healthy B cells remain unclear, therefore in this study, we explored how L-asparaginase modulates the biology and function of CD40-activated B cells, using an in-vitro model. B cells from healthy donors were treated with increasing L- asparaginase concentrations and analyzed for proliferation, immune phenotype, and metabolic changes. Results showed L-asparaginase reduced B cell proliferation and homotypic clustering without inducing apoptosis, instead impairing metabolic pathways, lowering glycolysis and oxidative phosphorylation, and reducing surface markers associated with antigen-presenting cell (APC) function. Functional assays confirmed that L-asparaginase- treated B cells had diminished ability to activate T cells. Supplementing with asparagine or glutamine restored B cell proliferation and function, with glutamine slightly more effective than asparagine. Interestingly, L-asparaginase induced a regulatory B cell phenotype, marked by CD24+CD38+CD27+ expression and increased interleukin-10 and TGF-beta, suggesting a potential immunosuppressive mechanism. These findings indicate that L-asparaginase not only affects malignant cells but also impacts the function of non-malignant B cells, proposing potential therapeutic applications in B cell-driven autoimmune disorders. Further studies are needed to explore its effects at lower, clinically relevant concentrations. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=132 SRC="FIGDIR/small/625617v1_ufig1.gif" ALT="Figure 1"> View larger version (19K): org.highwire.dtl.DTLVardef@1ae8d10org.highwire.dtl.DTLVardef@af405borg.highwire.dtl.DTLVardef@1aa4c0eorg.highwire.dtl.DTLVardef@16750ea_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 2.32
- Field percentile
- top 9%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Asparagine availability controls B cell homeostasis
Y. F. Yazicioglu, E. Marin, … A. Clarke·bioRxiv·Apr 3, 2023
- L-asparaginase treatment induces a tumor metabolic plasticity and reveals a vulnerability to PARP1/2 inhibitor Olaparib, in B-cell lymphomas.
Aussel Anaïs, Ivan Nemazanyy, … Johanna Chiche·bioRxiv·Oct 24, 2025
- The ASNS inhibitor ASX-173 potentiates L-asparaginase anticancer activity
Victor Vyacheslavovich Tatarskiy, Wai-Kin Chan, … Philip L. Lorenzi·bioRxiv·Jul 3, 2025
- Asparagine availability differentially regulates early vs late CD4+ and CD8+ T cell activation, metabolism and autophagy
Mingcheng Song, Linda V. Sinclair, … Robert J. Salmond·bioRxiv·Apr 29, 2026
- Depletion of extracellular asparagine impairs self-reactive T cells and ameliorates autoimmunity in a murine model of multiple sclerosis
Peter Georgiev, Sheila E. Johnson, … Arlene H. Sharpe·eLifePeer-reviewed·Jul 8, 2026
- Biphasic response of CD8 T cell to asparagine restriction maximizes its metabolic fitness and antitumoral functionality
J. R. Gnanaprakasam, L. Liu, … R. Wang·bioRxiv·Jul 18, 2022